LIPOLESS
Pioneered by Laboratorios Éticos • Distributed Exclusively by RCP farma
We Are Visionaries
Exclusive Metabolic Health Solutions for Africa, the Middle East & South America
Pioneered by Laboratorios Éticos | Strategically Distributed by RCP farma
For 20 years, RCP farma has delivered life-changing therapies to underserved regions. Now, as exclusive distributor of Lipoless (tirzepatide), we bring next-generation obesity and type 2 diabetes treatment to your markets—with full regulatory compliance and precision logistics.
1
Lipoless
RCP FARMA/LIPOLESS
Exclusive Metabolic Health Solutions for Africa, the Middle East & South America. Pioneered by Laboratorios Éticos | Strategically Distributed by RCPfarma. For 20 years, RCPfarma has delivered life-changing therapies to underserved regions. Now, as exclusive distributor of LIPOLESS (tirzepatide), we bring next-generation obesity and type 2 diabetes treatment to your markets with full regulatory compliance and precision logistics.
2
ABOUT RCP FARMA
RCP FARMA/LIPOLESS
20 Years Defining Regional Distribution. Your Bridge to Underserved Markets
Since 2004, RCP farma has optimized access to critical medicines across Africa, the Middle East, and South America. We specialize in: Targeted Therapeutic Distribution: Diabetes & obesity therapeutics (88% of portfolio)
Hyper-Localized Compliance: Regulatory approvals in 37 countries with 99.2% renewal rate Climate-Adaptive Logistics: Temperature-controlled transport across desert, tropical & high-altitude regions. Manufacturer Synergy: 60+ long-term partnerships with ethical laboratories.
3
Our Services
RCP FARMA/LIPOLESS
Precision Distribution for Complex Markets
Exclusive Territory Management
Contract-backed rights with sales performance analytics.
Accelerated Market Entry
Regulatory pathway mapping (avg. 47% faster approvals vs. industry benchmarks).
Guaranteed Supply Integrity
IATA-compliant cold chain; real-time shipment monitoring; 30+ warehouse hubs.
Therapeutic Adoption Programs
Clinician training modules (CME-accredited)
Patient adherence support
Health-economic dossier development
Safety & Surveillance
Local-language pharmacovigilance aligned with WHO-UMC standards.
Exclusive rights across Africa, the Middle East, and South America leveraging 20 years of specialized distribution networks in diabetes/obesity therapeutics.
End-to-End Regulatory Leadership
DINAVISA-authorized (Paraguay) with active registrations underway in all territories. FDA/EMA-approved formula.
Therapeutic Expertise
Focused exclusively on metabolic health since 2004: 83% portfolio alignment with diabetes/weight management innovations.
Patient-Centric Solutions
Flexible dosing (2.5mg–15mg) in auto-injectors + cold chain logistics for tropical climates.
Partnership Infrastructure
Localized patient access programs, clinician training, and pharmacovigilance in 12 languages.
Marcel E. KHOURY
chairman & founder of RCP FARMA
